Bicara Therapeutics

BCAXPhase 3

Bicara Therapeutics is pioneering a new class of bifunctional biologics that integrate tumor-targeting precision with microenvironment-modulating power to overcome cancer resistance. The company's lead program, BCA101, is advancing through Phase 1/2 clinical trials for head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and anal cancer. With a strong leadership team of experienced biotech executives and scientists, Bicara is positioned to address significant unmet needs in oncology through its innovative therapeutic approach.

Market Cap

$1.2B

Employees

50-100

Focus

AntibodiesBiologics

BCAX · Stock Price

USD 18.415.00 (-21.36%)

Historical price data

AI Company Overview

Technology Platform

Bifunctional biologics platform combining tumor-targeting antibodies with immune-modulating domains to simultaneously attack cancer cells and reprogram the tumor microenvironment.

Pipeline Snapshot

2 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Ficerafusp alfa + Pembrolizumab (KEYTRUDA®) + Placebo	Metastatic Head and Neck Squamous Cell Carcinoma	Phase 2/3
Ficerafusp alfa + Pembrolizumab	Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2

Funding History

Total raised: $139M

Series B$108MRedmile GroupJan 15, 2022

Series A$31MRA Capital ManagementOct 15, 2020

Opportunities

Bicara has significant growth opportunities through expansion of its bifunctional platform to additional tumor targets and immune modulators, potential combination strategies with other immuno-oncology agents, and entry into broader EGFR-driven tumor indications beyond current clinical programs.

Risk Factors

Key risks include clinical trial failures for lead candidate BCA101, safety concerns related to TGF-β inhibition, manufacturing challenges for complex bifunctional biologics, and intense competition in the oncology immunotherapy space from larger pharmaceutical companies.

Competitive Landscape

Bicara faces competition from major pharmaceutical companies developing combination therapies (Merck, Bristol-Myers Squibb) and other bifunctional/bi-specific developers, but differentiates through its first-in-class EGFR/TGF-β-trap mechanism and targeted delivery approach that may offer improved safety and efficacy profiles.

Publications

Pipeline